Payal Kohli, MD
Cardiovascular Disease · Aurora, CONPI 1447459771
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,133,873 of the $1,718,232 with a category attached, or 66.0%. It is spread thinly across 27 manufacturers, the largest accounting for just 19.4%. 2025 is the largest year on record at $522,838, more than ten times the $22,470 reported in 2019. Among cardiovascular disease clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,729 payments — averaging $993.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$333K
- Esperion Therapeutics, Inc.$296K
- Merck$218K
- Amarin Pharma, Inc.$161K
- Bayer$153K
- Lilly USA, LLC$101K
- plus $457K from 21 others
What the payments were for
- Consulting fees$300,15917%
- Speaking & faculty fees$1,133,87366%
- Travel & lodging$245,46114%
- Food & beverage$33,6282%
- Education$5,1110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 378 | $332,550 |
| Esperion Therapeutics, Inc. | 265 | $295,971 |
| Merck | 207 | $217,603 |
| Amarin Pharma, Inc. | 133 | $160,573 |
| Bayer | 123 | $152,999 |
| Lilly USA, LLC | 128 | $101,292 |
| Novo Nordisk | 63 | $93,623 |
| Boston Scientific | 99 | $87,401 |
| E.r. Squibb & Sons, L.L.C. | 45 | $63,380 |
| Heartflow, Inc. | 39 | $47,539 |
| AstraZeneca | 56 | $46,304 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 74 | $44,516 |
| Boehringer Ingelheim | 22 | $25,905 |
| Novartis | 26 | $25,882 |
| Agepha Pharma FZ LLC | 13 | $15,022 |
| Idorsia Pharmaceuticals US Inc | 2 | $3,179 |
| Abbott | 20 | $1,670 |
| Medtronic(2 entities) | 5 | $1,187 |
| Biotronik Inc. | 11 | $753 |
| Artivion, Inc. | 4 | $526 |
| Philips North America LLC | 5 | $124 |
| Lexicon Pharmaceuticals, Inc. | 2 | $69 |
| Pfizer | 3 | $57 |
| Scpharmaceuticals Inc. | 3 | $45 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $22 |
| Medicure Pharma Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$315,261
- NEXLETOL$293,198
- NEXLIZET$292,721
- VERQUVO$251,464
- Vascepa$159,018
- Kerendia$138,525
- ZEPBOUND$97,544
- FFRct$47,054
- WATCHMAN Access System$45,400
- FARXIGA$45,362
- Ozempic$44,208
- LifeVest$43,512
- Watchman$35,585
- LEQVIO$16,876
- LODOCO$14,938
- CAMZYOS$12,962
- GENERAL - THERAPIES$3,465
- Tryvio$3,179
- GENERAL VASCULAR ACCESS$1,239
- Mitra Clip system$1,192
How this compares
$1,718,232 in reported general payments places this provider in the 95th percentile of 276 cardiovascular disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 146 | $140,542 |
| FarxigaDapagliflozin Propanediol | 122 | $109,480 |
| Repatha SureclickEvolocumab | 154 | $99,386 |
| JardianceEmpagliflozin | 18 | $26,134 |
| WegovySemaglutide | 16 | $21,057 |
| OzempicSemaglutide | 21 | $19,154 |
| Praluent PenAlirocumab | 28 | $14,430 |
| EntrestoSacubitril/Valsartan | 13 | $8,782 |
| DapagliflozinDapagliflozin Propanediol | 12 | $6,259 |
| Rosuvastatin Calcium | 220 | $2,981 |
| Ezetimibe | 177 | $2,680 |
| Atorvastatin Calcium | 236 | $1,663 |
| Metoprolol Succinate | 151 | $1,443 |
| Losartan Potassium | 168 | $896 |
| Amlodipine Besylate | 98 | $469 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $57 | $140,542146 claims |
| AstraZenecaFarxiga | $46,304 | $109,480122 claims |
| Novo NordiskWegovy, Ozempic | $93,623 | $40,21137 claims |
| Boehringer IngelheimJardiance | $25,905 | $26,13418 claims |
| NovartisEntresto | $25,882 | $8,78213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 276 cardiovascular disease providers in Colorado.
Other cardiovascular disease in Aurora
- Marc BonacaAurora$703K
- William SauerAurora$365K
- Rhonda MiyasakaAurora$128K
- Gregory SchwartzAurora$122K
- Edward GillAurora$96K
- Joseph AdewumiAurora$61K
- Charles FuenzalidaAurora$30K
- Christina HealyAurora$25K
- Sundeep ViswanathanAurora$21K
- Nelson PragerAurora$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.